01:12 AM EDT, 08/11/2026 (MT Newswires) -- Paxman (PAX.ST) said Monday that the US Food and Drug Administration will implement the De Novo process to review its Limb Cryocompression System for the reduction of chemotherapy-induced peripheral neuropathy. The Swedish scalp cooling company noted that the regulatory pathway will stretch its approval timeline. However, a potential approval could make Paxman the first company to lower or prevent chemotherapy-induced peripheral neuropathy using cryocompression technology in the US. The Limb Cryocompression System is already approved for the said indication in the UK and Europe.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.